New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
04:55 EDTBLUE, BLUE, BLUE, BLUE, ACE, ACE, ACE, ACE, XLRN, XLRN, XLRN, XLRN, TGTX, TGTX, TGTX, TGTX, NVS, NVS, NVS, NVS, AGIO, AGIO, AGIO, AGIO, AG, AG, AG, AGEuropean Hematology Association to hold a conference
19th Congress of the European Hematology Association will be held in Milan, Italy on June 12-15.
News For BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG From The Last 14 Days
Check below for free stories on BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 15, 2014
07:31 EDTTGTXTG Therapeutics commences clinical study that combines TG-1101, TGR-1202
Subscribe for More Information
August 14, 2014
10:05 EDTXLRNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:36 EDTXLRNAcceleron initiated with an Outperform at FBR Capital
Target $47.
August 13, 2014
08:34 EDTAGIOAgios announces AG-221 fast track designation from FDA
Subscribe for More Information
07:22 EDTAGFirst Majestic reports Q2 total production 3.86M silver equivalent ounces
The production growth was primarily due to higher throughput rates at Del Toro and San Martin following each of their respective expansions. Total ore processed during the second quarter amounted to 671,024 tonnes, representing a 5% increase compared to the previous quarter primarily driven by higher throughputs at Del Toro and San Martin.
07:22 EDTAGFirst Majestic reports Q2 adjusted EPS 2c, consensus 7c
Subscribe for More Information
August 12, 2014
16:17 EDTBLUEbluebird bio reports Q2 EPS (6c), consensus (45c)
Subscribe for More Information
07:01 EDTXLRNAcceleron reports Q2 EPS (52c), consensus (45c)
Subscribe for More Information
August 11, 2014
15:27 EDTBLUEWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
August 7, 2014
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
07:37 EDTAGIOAgios Pharmaceuticals reports Q2 EPS (54c), consensus (41c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use